PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:22 AM ET

Sponsor Check › Person

LE
No photo found yet (own website and image search run after this page is viewed)

Lars Ekman

Named as an officer, director or promoter on SEC Form D filings · CA · Oct 30, 2009 → Dec 22, 2025

7deals (issuers)
$335.4Mreported sold
115investors
17Form D filings
2009–2025years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:03 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Lars Ekman is listed as an executive officer and director on 17 SEC Form D filings by 7 issuers between Oct 2009 and Dec 2025. Largest by amount reported sold: Poseida Therapeutics, Inc. (San Diego, CA — biotechnology — 2015–2017; $142.1M reported sold to 17 investors), AMARIN CORP PLC\UK (Dublin, Ireland (as filed: L2) — pharmaceuticals — 2009; $70M reported sold to 36 investors), Aeovian Pharmaceuticals, Inc. (Berkeley, CA — pharmaceuticals — 2025; $55M reported sold to 13 investors), CEBIX Inc (San Diego, CA — biotechnology — 2009–2014; $33.2M reported sold to 10 investors), Ocera Therapeutics, Inc. (Palo Alto, CA — biotechnology — 2013; $28M reported sold to 31 investors) and 2 more (all listed below).

What this means A repeat sponsor — 7 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $335.4M sold in total.

Listed alongside Nina Kjellson (10 shared filings), Pratik Shah (10 shared filings), Anne M. VanLent (5 shared filings), David Moore (5 shared filings), Eckard Weber (5 shared filings) and 50 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Lars. Each name links to their own page.

1 of the issuers belongs to the sponsor group Ocera Therapeutics (2 issuers, $29.5M reported sold, 2010–2013).

What this means A sponsor group is one team that sets up a new company for each deal. Ocera Therapeutics has 2 companies on file and $29.5M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 17 public filings for Lars Ekman and found 16 differences, 3 worth asking the sponsor about: Amount sold went down between filings; Investor count went down between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Lars Ekman has not run yet — it is joining a line of 52,610 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:03 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Lars Ekman..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:03 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

16 differences found between the filings for Lars Ekman — 3 worth asking about (compared 17 filings on Oct 24, 2026)

Worth asking · Aug 31, 2010 – Mar 9, 2012

Amount sold went down between filings — CEBIX Inc

The Aug 31, 2010 filing says $13,999,998 sold; the Mar 9, 2012 Form D/A says $8,799,305 sold — $5,200,693 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D/A (earlier) · Aug 31, 2010 ↗Form D/A (later) · Mar 9, 2012 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Worth asking · Aug 31, 2010 – Mar 9, 2012

Investor count went down between filings — CEBIX Inc

The Aug 31, 2010 filing reports 7 investors; the Mar 9, 2012 Form D/A reports 5 investors.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D/A (earlier) · Aug 31, 2010 ↗Form D/A (later) · Mar 9, 2012 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Aug 30, 2010

Lars Ekman appears on 1 deal that stopped filing before reaching its target

ARYx Therapeutics, Inc. (last filing Aug 30, 2010; $2,012,500 sold of $35,357,446). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

ARYx Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jun 4, 2009 – Dec 22, 2025

5 Form Ds were filed more than 15 days after the first sale

Form D filed 148 days after the first sale — CEBIX Inc · Form D filed 34 days after the first sale — Aeovian Pharmaceuticals, Inc. · Form D filed 17 days after the first sale — CEBIX Inc · Form D filed 17 days after the first sale — ARYx Therapeutics, Inc. · Form D filed 38 days after the first sale — ARYx Therapeutics, Inc.

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Oct 30, 2009 ↗CEBIX Inc — PartnerFacts page ↗Form D · Dec 22, 2025 ↗Aeovian Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jun 4, 2009 – Aug 3, 2017

9 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Poseida Therapeutics, Inc. (latest filing Aug 3, 2017) · No amendment in the last 12 months on an offering that may still be open — Poseida Therapeutics, Inc. (latest filing Dec 24, 2015) · No amendment in the last 12 months on an offering that may still be open — CEBIX Inc (latest filing Nov 13, 2014) · No amendment in the last 12 months on an offering that may still be open — Ocera Therapeutics, Inc. (latest filing Jul 24, 2013) · No amendment in the last 12 months on an offering that may still be open — Ocera Therapeutics, Inc. (latest filing Jul 16, 2013) · and 4 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Aug 3, 2017 ↗Poseida Therapeutics, Inc. — PartnerFacts page ↗Form D · Dec 24, 2015 ↗Form D/A · Nov 13, 2014 ↗
Sources
Note · Mar 9, 2012 – Sep 13, 2012

Lars Ekman's role changed at CEBIX Inc: executive officer, director → director

The Mar 9, 2012 filing lists Lars Ekman as executive officer, director; the Sep 13, 2012 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D/A · Mar 9, 2012 ↗Form D · Sep 13, 2012 ↗Lars Ekman — PartnerFacts page ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Sep 13, 2012 – Nov 13, 2014

Offering amount changed between filings — CEBIX Inc

The Sep 13, 2012 filing says $30,938,334 offered; the Nov 13, 2014 Form D/A says $34,938,807.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Sep 13, 2012 ↗Form D/A (later) · Nov 13, 2014 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Aug 31, 2010 – Mar 9, 2012

Offering amount lowered between filings — CEBIX Inc

The Aug 31, 2010 filing says $13,999,998 offered; the Mar 9, 2012 Form D/A says $9,000,000.

What this means The target raise got smaller. That can mean the plan shrank or the sponsor stopped early. Ask what changed in the deal.

Form D/A (earlier) · Aug 31, 2010 ↗Form D/A (later) · Mar 9, 2012 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Oct 30, 2009 – Aug 31, 2010

Offering amount changed between filings — CEBIX Inc

The Oct 30, 2009 filing says $7,400,000 offered; the Aug 31, 2010 Form D/A says $13,999,998.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Oct 30, 2009 ↗Form D/A (later) · Aug 31, 2010 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Oct 30, 2009

Lars Ekman is written 2 different ways on the filings

listed as "Lars G. Ekman" on 6 filings (from Oct 30, 2009), and "Lars Ekman" on 11 filings (from Oct 30, 2009).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Oct 30, 2009 ↗Form D · Oct 30, 2009 ↗Lars Ekman — PartnerFacts page ↗
Sources
Note · Jul 16, 2013 – Nov 21, 2013

Industry group changed between filings — Ocera Therapeutics, Inc.

"Pharmaceuticals" (Jul 16, 2013 to Jul 24, 2013); then "Biotechnology" (Nov 21, 2013).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Jul 16, 2013 ↗Form D · Nov 21, 2013 ↗Ocera Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Oct 30, 2009 – Sep 13, 2012

Industry group changed between filings — CEBIX Inc

"Pharmaceuticals" (Oct 30, 2009 to Mar 9, 2012); then "Biotechnology" (Sep 13, 2012 to Nov 13, 2014).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Oct 30, 2009 ↗Form D · Sep 13, 2012 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Jul 16, 2013 – Nov 21, 2013

Reported revenue range changed between filings — Ocera Therapeutics, Inc.

"$5,000,001 - $25,000,000" (Jul 16, 2013); then "Decline to Disclose" (Nov 21, 2013).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Jul 16, 2013 ↗Form D · Nov 21, 2013 ↗Ocera Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Dec 24, 2015 – Aug 3, 2017

Address moved from La Jolla, CA to San Diego, CA — Poseida Therapeutics, Inc.

The people listed on the Dec 24, 2015 filing give La Jolla, CA; on the Aug 3, 2017 filing they give San Diego, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Dec 24, 2015 ↗Form D · Aug 3, 2017 ↗Poseida Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Sep 13, 2012 – Nov 13, 2014

Address moved from La Jolla, CA to San Diego, CA — CEBIX Inc

The people listed on the Sep 13, 2012 filing give La Jolla, CA; on the Nov 13, 2014 filing they give San Diego, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Sep 13, 2012 ↗Form D/A · Nov 13, 2014 ↗CEBIX Inc — PartnerFacts page ↗
Sources
Note · Jul 24, 2013 – Nov 21, 2013

Address moved from San Diego, CA to Palo Alto, CA — Ocera Therapeutics, Inc.

The people listed on the Jul 24, 2013 filing give San Diego, CA; on the Nov 21, 2013 filing they give Palo Alto, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jul 24, 2013 ↗Form D · Nov 21, 2013 ↗Ocera Therapeutics, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

3 of 13 offerings report sales commissions totalling $2,920,000; 2 report finder's fees totalling $860,000; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Dec 22, 2025 D
Aeovian Pharmaceuticals, Inc.
File 021-567748
$0$0$0None listed on this filingEDGAR ↗
Sep 6, 2019 D
SOPHIRIS BIO INC.
File 021-348192
$240,000$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗EDGAR ↗
Aug 3, 2017 D
Poseida Therapeutics, Inc.
File 021-292050
$0$0$0None listed on this filingEDGAR ↗
Dec 24, 2015 D
Poseida Therapeutics, Inc.
File 021-253835
$0$0$0None listed on this filingEDGAR ↗
Nov 13, 2014 D/A
CEBIX Inc
File 021-184060
$0$0$0None listed on this filingEDGAR ↗
Nov 21, 2013 D
Ocera Therapeutics, Inc.
File 021-206724
$1,380,000$0$0 (est.)
The Issuer will use a portion of the gross proceeds for working capital and general corporate purposes, including payments to executive officers and directors in the ordinary course of business.
Stifel, Nicolaus & Company Incorporated BrokerCheck CRD 793 ↗
Cowen & Company LLC BrokerCheck CRD 7616 ↗		EDGAR ↗
Jul 24, 2013 D
Ocera Therapeutics, Inc.
File 021-200184
$0$0$0None listed on this filingEDGAR ↗
Jul 16, 2013 D/A
Ocera Therapeutics, Inc.
File 021-199732
$0$0$0None listed on this filingEDGAR ↗
Jul 16, 2013 D
Ocera Therapeutics, Inc.
File 021-199755
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2012 D/A
CEBIX Inc
File 021-121648
$0$0$0None listed on this filingEDGAR ↗
Aug 30, 2010 D
ARYx Therapeutics, Inc.
File 021-147064
$0$0$0None listed on this filingEDGAR ↗
Nov 13, 2009 D
ARYx Therapeutics, Inc.
File 021-124990
$0$350,000 (est.)$0
Proceeds from the subject financing are to be used for working capital and other general corporate purposes.
Reedland Capital Partners no CRD number reported
via Financial West Group (CRD 16668 ↗)
EDGAR ↗
Oct 30, 2009 D
AMARIN CORP PLC\UK
File 021-135720
$1,300,000$510,000$0Cowen and Company LLC BrokerCheck CRD 1716 ↗EDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 7

Every issuer that named Lars Ekman on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

AP
Pharmaceuticals

Aeovian Pharmaceuticals, Inc.

Berkeley, CA · Dec 22, 2025
  • Dec 22, 2025 · D · $54,999,996 sold of $54,999,996 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $55M from 13 investors (100% of the $55M target) as of the latest filing. Lars is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

SOPHIRIS BIO INC.

La Jolla, CA · Sep 6, 2019
  • Sep 6, 2019 · D · $5,066,667 sold of $5,066,667 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5.07M from 1 investor (100% of the $5.07M target) as of the latest filing. Lars is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PT
Biotechnology

Poseida Therapeutics, Inc.

San Diego, CA · Dec 24, 2015 → Aug 3, 2017 · 2 filings
  • Aug 3, 2017 · D · $11,160,002 sold of $15,000,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2015 · D · $23,033,232 sold of $36,033,230 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $142.1M from 17 investors (100% of the $15M target) as of the latest filing. Lars is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

C
Biotechnology

CEBIX Inc

San Diego, CA · Oct 30, 2009 → Nov 13, 2014 · 5 filings
  • Nov 13, 2014 · D/A · $33,188,334 sold of $34,938,807 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 13, 2012 · D · $12,938,338 sold of $30,938,334 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 9, 2012 · D/A · $8,799,305 sold of $9,000,000 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Aug 31, 2010 · D/A · $13,999,998 sold of $13,999,998 · 7 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Oct 30, 2009 · D · $7,400,000 sold of $7,400,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $33.2M from 10 investors (95% of the $34.9M target) as of the latest filing. Lars is listed as director, executive officer on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OT
Biotechnology · group: Ocera Therapeutics

Ocera Therapeutics, Inc.

Palo Alto, CA · Jul 16, 2013 → Nov 21, 2013 · 5 filings
  • Nov 21, 2013 · D · $28,000,000 sold of $28,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 24, 2013 · D · $0 sold of Indefinite · 31 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 16, 2013 · D · $20,000,000 sold of Indefinite · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 16, 2013 · D/A · $0 sold of Indefinite · 25 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 16, 2013 · D · $0 sold of Indefinite · 25 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $28M from 31 investors (100% of the $28M target) as of the latest filing. Lars is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Pharmaceuticals

ARYx Therapeutics, Inc.

Fremont, CA · Nov 13, 2009 → Aug 30, 2010 · 2 filings
  • Aug 30, 2010 · D · $2,012,500 sold of $5,025,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 13, 2009 · D · $357,446 sold of $35,357,446 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2.01M from 7 investors (40% of the $5.03M target) as of the latest filing. Lars is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AC
Pharmaceuticals

AMARIN CORP PLC\UK

Dublin, Ireland (as filed: L2) · Oct 30, 2009
  • Oct 30, 2009 · D · $70,000,000 sold of $70,000,000 · 36 investors · min. $50,000 · role: Director EDGAR ↗

Raised $70M from 36 investors (100% of the $70M target) as of the latest filing. Lars is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around Lars 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

NK
No photo found yet (own website and image search run after this page is viewed)
Person

Nina Kjellson

Director · 10 shared filings (2 issuers) · also on 12 other issuers

Nina Kjellson is on 14 issuers in total — a repeat sponsor. Their page lists every one.

PS
No photo found yet (own website and image search run after this page is viewed)
Person

Pratik Shah

Director · 10 shared filings (2 issuers) · also on 6 other issuers

Pratik Shah is on 8 issuers in total — a repeat sponsor. Their page lists every one.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

David Moore

Executive Officer · 5 shared filings (1 issuer) · also on 5 other issuers

David Moore is on 6 issuers in total — a repeat sponsor. Their page lists every one.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Michael F. Powell

Director · 5 shared filings (1 issuer) · also on 5 other issuers

Michael F. Powell is on 6 issuers in total — a repeat sponsor. Their page lists every one.

EW
No photo found yet (own website and image search run after this page is viewed)
Person

Eckard Weber

Director · 5 shared filings (1 issuer) · also on 10 other issuers

Eckard Weber is on 11 issuers in total — a repeat sponsor. Their page lists every one.

LG
No photo found yet (own website and image search run after this page is viewed)
Person

Linda S. Grais

Executive Officer, Director · 5 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

WR
No photo found yet (own website and image search run after this page is viewed)
Person

William R. Rohn

Executive Officer, Director · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

Jean-Paul Castaigne

Director · 5 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

AV
No photo found yet (own website and image search run after this page is viewed)
Person

Anne M. VanLent

Director, Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

FR
No photo found yet (own website and image search run after this page is viewed)
Person

Franck S. Rousseau

Executive Officer, Director · 5 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

James Healy

Director, Executive Officer · 4 shared filings (2 issuers) · also on 16 other issuers

James Healy is on 18 issuers in total — a repeat sponsor. Their page lists every one.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

Dana McGowan

Executive Officer · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JW
No photo found yet (own website and image search run after this page is viewed)
Person

John Wahren

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

KL
No photo found yet (own website and image search run after this page is viewed)
Person

Keith Leonard

Director · 2 shared filings (1 issuer) · also on 4 other issuers

Keith Leonard is on 5 issuers in total — a repeat sponsor. Their page lists every one.

NS
No photo found yet (own website and image search run after this page is viewed)
Person

Nick Simon

Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

Joel Martin

Executive Officer, Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

PD
No photo found yet (own website and image search run after this page is viewed)
Person

Pascal Druzgala

Executive Officer · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Lars Ekman. Their page shows their other deals.

PG
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Goddard

Executive Officer, Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

DN
No photo found yet (own website and image search run after this page is viewed)
Person

David Nagler

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JV
No photo found yet (own website and image search run after this page is viewed)
Person

John Varian

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

PS
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Sekhri

Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

DK
No photo found yet (own website and image search run after this page is viewed)
Person

David Kabakoff

Director · 2 shared filings (1 issuer) · also on 11 other issuers

David Kabakoff is on 12 issuers in total — a repeat sponsor. Their page lists every one.

MM
No photo found yet (own website and image search run after this page is viewed)
Person

Michelle Morgan

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

NS
No photo found yet (own website and image search run after this page is viewed)
Person

Nishan de Silva

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Lars Ekman. Their page shows their other deals.

EO
No photo found yet (own website and image search run after this page is viewed)
Person

Eric Ostertag

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

DB
No photo found yet (own website and image search run after this page is viewed)
Person

David Beier

Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JK
No photo found yet (own website and image search run after this page is viewed)
Person

John Kincaid

Executive Officer · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

YB
No photo found yet (own website and image search run after this page is viewed)
Person

Youssef Bennani

Director · 1 shared filing (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

TK
No photo found yet (own website and image search run after this page is viewed)
Person

Themasap Khan

Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

NR
No photo found yet (own website and image search run after this page is viewed)
Person

Nils Regge

Director · 1 shared filing (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

WG
No photo found yet (own website and image search run after this page is viewed)
Person

William Greene

Director · 1 shared filing (1 issuer) · also on 10 other issuers

William Greene is on 11 issuers in total — a repeat sponsor. Their page lists every one.

MZ
No photo found yet (own website and image search run after this page is viewed)
Person

Micah Zajic

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

JG
No photo found yet (own website and image search run after this page is viewed)
Person

Justin Gover

Director · 1 shared filing (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

AH
No photo found yet (own website and image search run after this page is viewed)
Person

Allison J. Hulme

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

RG
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Gaster

Director · 1 shared filing (1 issuer) · also on 5 other issuers

Richard Gaster is on 6 issuers in total — a repeat sponsor. Their page lists every one.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carl L. Gordon

Director · 1 shared filing (1 issuer) · also on 61 other issuers

Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Jim Heppell

Director · 1 shared filing (1 issuer) · also on 8 other issuers

Jim Heppell is on 9 issuers in total — a repeat sponsor. Their page lists every one.

HR
No photo found yet (own website and image search run after this page is viewed)
Person

Herm Rosenman

Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Lars Ekman. Their page shows their other deals.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Milner

Executive Officer, Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Lars Ekman. Their page shows their other deals.

DC
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel Canafax

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Lars Ekman. Their page shows their other deals.

The team behind the deals

OT
Sponsor group

Ocera Therapeutics

2 issuers · 7 filings · $29.5M reported sold · 2010–2013

One team, 2 deal companies. Lars Ekman is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Lars Ekman.

Same business address

30 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 7 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Lars Ekman by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 7 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Lars Ekman is listed on: none on file. No website or social profile named in AMARIN CORP PLC\UK's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #366,991 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Dublin, L2). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Lars Ekman appears on a new Form D, or when a court case or SEC action is matched to them. See plans →